In February 2025, AlzeCure was awarded a EUR 2.5 million grant from the European Innovation Council (EIC) for NeuroRestore ACD856. The awarded grant is a strong validation of the project and the funding aims to support a planned phase IIa study with ACD856 in Alzheimer’s patients. Furthermore, higher doses of the substance will also be evaluated in humans, as the good safety profile allows for further dosing.
AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders
AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction
Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.
